Bengaluru: Vir Biotechnology said on Wednesday it had signed a collaboration agreement worth up to USD 1.88 billion with Gilead Sciences to discover and develop new cancer treatments for solid...
Summary as published by Business Medical Dialogues.
Read the full story
The complete article is on Business Medical Dialogues's website.
Related stories
Plants & AgricultureThe Economic Times
Bayer partners with Absolute’s INERA to expand biological crop nutrition in India
Bayer will market and distribute a biological crop nutrition solution developed by Absolute’s agricultural biotechnology arm INERA, aiming to expand access to inputs designed to improve nutrient-use efficiency and support climate-resilient farming. The collaboration combines INERA’s biological research with Bayer’s distribution network, though pricing, product performance data and sales targets remain undisclosed.
Plants & AgricultureLatestly
Business News | Herbalife India Launches Phyto Innovation Accelerator with IIT Madras to Advance India's Plant Biotechnology Ecosystem
Get latest articles and stories on Business at LatestLY. Chennai (Tamil Nadu) [India], October 15: Herbalife International India Pvt. Ltd. and the Indian Institute of Technology Madras (IIT Madras) launched the Herbalife–IIT Madras Phyto Innovation Accelerator Programme, an industry-academia initiative to translate plant biotechnology research into scalable solutions for health, wellness and sustainable…
Biotech & IndustryDevdiscourse
Herbalife India Launches Phyto Innovation Accelerator with IIT Madras to Advance India's Plant Biotechnology Ecosystem
PRNewswire Chennai Tamil Nadu India October 15 Herbalife International India Pvt Ltd and the Indian Institute of Technology Madras IIT Madras launched the HerbalifeIIT Madras Phyto Innovation Accelerator Programme an industry-academia initiative to translate plant biotechnology research into scalable solutions for health wellness and sustainable biomanufacturing Shri Pralhad Joshi Union Minister of Education…
- Immunology & Vaccines
Pharma Biz
Calluna Pharma completes dosing in phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis
Calluna Pharma AS (Calluna), a clinical─stage biotechnology company pioneering first─in─class antibodies for inflammatory and fibrotic diseases, announced completion of dosing in the phase 2 AURORA study of